Abstract
RT-PCR remains the gold standard for determining the etiology of respiratory viral infections caused by SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV). While multiplex testing panels allow for the detection of co-infections at the point of care (POC), standard turnaround times often delay critical treatment decisions. The AMDI Fast PCR Mini Respiratory Panel is a 10-minute RT-PCR test designed for POC use, utilizing a single anterior nasal swab and an integrated cloud-connected instrument. In a multi-center clinical study of 1,906 participants, the AMDI system was compared against the Cepheid Xpert Xpress CoV-2/Flu/RSV plus. The AMDI panel demonstrated overall percent agreements of 97.2% for Flu A, 99.7% for Flu B, 99.3% for RSV, and 99.3% for SARS-CoV-2. These results indicate that the AMDI Fast PCR Mini Respiratory Panel provides high-sensitivity molecular diagnostics in under 10 minutes, facilitating rapid clinical intervention.
Introduction
Accurate diagnosis of respiratory viruses is essential for the timely administration of antiviral therapies and the implementation of public health measures. However, traditional laboratory-based RT-PCR often requires 24–48 hours for results, missing the optimal window for "test-to-treat" scenarios. Even existing POC molecular tests typically require 20 to 40 minutes, creating bottlenecks in high-volume clinical settings like urgent care. This study evaluates the AMDI Fast PCR system, which aims to deliver PCR-level sensitivity within the 10-minute timeframe usually associated with less reliable rapid antigen tests.
Methods and System Overview
The AMDI Fast PCR system is a modular platform consisting of a Base Station, up to four Operating Modules, and an iPad-based user interface. The core of the technology is a single-use disposable "Disc" that integrates sample processing, reverse transcription, amplification, and dual-channel optical detection.
Following sample collection, raw data is transmitted to the AMDI Cloud for processing via a proprietary algorithm. Results are returned to the clinician’s iPad and the patient's Electronic Health Record (EHR) within seconds. The entire workflow requires less than one minute of hands-on time and provides a total sample-to-answer result in approximately 10 minutes.
Clinical Study Design and Datasets
The clinical performance of the AMDI system was established through a multicenter trial conducted across nine US sites, including urgent care, pediatric, and adult clinics. The study enrolled a total of 2,079 participants, ultimately yielding 1,906 evaluable anterior nasal swab (ANS) pairs for comparison against the FDA-cleared Cepheid Xpert Xpress.
The evaluable cohort included 1,788 prospective samples collected from symptomatic individuals between December 2024 and May 2025, supplemented by 118 archived samples to ensure adequate representation of lower-prevalence targets like RSV and Flu B. The study population was demographically diverse, with a median age of 35 and 61.3% female participation.
Results
The AMDI Fast PCR Mini Respiratory Panel showed excellent concordance with the industry-standard comparator across all targets. The quantitative relationship between the platforms was further confirmed by regression analysis of Cycle Threshold (Ct) values, which showed slopes near unity (0.98–1.20), indicating consistent performance despite the AMDI system's accelerated thermal cycling.
Clinical Performance Summary
| Analyte | PPA (Sensitivity) | NPA (Specificity) | Overall Agreement |
|---|---|---|---|
| Flu A | 97.5% | 97.2% | 97.2% |
| Flu B | 100.0% | 99.7% | 99.7% |
| RSV | 93.0% | 99.5% | 99.3% |
| SARS-CoV-2 | 97.7% | 99.4% | 99.3% |
Analysis of the 85 discrepant results (4.4% of the total) revealed that 72% (61 samples) were associated with low viral loads (Ct > 37). This suggests that disagreements between the two platforms primarily occur at the extreme limit of detection, where biological noise and sampling variability—often referred to as the "two-swab problem"—are most significant.
Discussion and Conclusion
The study demonstrates that the AMDI Fast PCR system can deliver high-sensitivity molecular results in 10 minutes without compromising clinical utility. The system's operational simplicity was highlighted by the successful participation of 28 different operators who received no formal training beyond a Quick Reference Guide.
While the study was limited by the inherent variability of using two separate swabs for comparison and the lack of a third "tie-breaker" method for discrepant results, the high degree of agreement with the Cepheid comparator is compelling. The AMDI Fast PCR Mini Respiratory Panel effectively bridges the gap between the speed of antigen testing and the accuracy of laboratory PCR, providing a robust tool for immediate clinical decision-making at the point of care.
Summary updated